Since 1992, the 340B Drug Pricing Program has played a modest, but increasingly important, role in the U.S. healthcare market. This whitepaper provides a brief overview of the program since inception; the impact of the program on various stakeholders; and presents a forward-looking view on the program given recent public reports and discussion, administration actions and potential legislative changes.